Document:

exv4w1

Exhibit 4.1

DONEGAL GROUP INC.

2011 AGENCY STOCK PURCHASE PLAN

1. Purpose.

     Donegal Group Inc. (the “Company”) established this 2011 Agency Stock Purchase Plan (this
“Plan”) for the benefit of eligible independent insurance agencies of the Company and Donegal
Mutual Insurance Company (“Donegal Mutual”) and their respective subsidiaries, any insurance
company that the Company or Donegal Mutual owns 50% or more of such company’s stock or any company
from which the Company or Donegal Mutual assumes 100% quota share reinsurance (collectively, the
“Companies”). This Plan provides an Eligible Agency, as defined in Section 2, an opportunity to
acquire a long-term proprietary interest in the Company through the purchase of the Company’s Class
A common stock (the “Class A common stock”) at a discount from current market prices. In offering
this Plan, the Company seeks to foster the common interests of the Company and Eligible Agencies in
achieving long-term profitable growth for the Company. Accordingly, the Company has created this
Plan to facilitate the purchase and long-term investment in shares of the Class A common stock by
Eligible Agencies.

2. Eligible Agencies.

     An Eligible Agency is an agency that, the Company determines, in its discretion, brings value
to the Companies and with which the Companies seek a long-term relationship. The Company will
consider the following criteria to determine eligibility:

	 	(i)	 	the agency’s premium volume;
	 
	 	(ii)	 	the potential growth of such premium volume;
	 
	 	(iii)	 	the profitability of the agency’s business; and
	 
	 	(iv)	 	whether the Company has placed the agency on rehabilitation or revoked the
agency’s binding authority.

The Company, in its discretion, may base eligibility on agency segmentation class or any other
factors that indicate value, directly or indirectly, to the Companies. The Company will conduct
periodic reviews to determine the continued eligibility of each Eligible Agency. A pattern of
immediate resale of the Class A common stock acquired under this Plan by an Eligible Agency will be
a factor in the Company’s determination whether an agency should remain eligible for continued
participation in this Plan because immediate resales would tend to indicate that an Eligible Agency
is not seeking to share in the long-term profitable growth of the Companies. The Company will
treat its decision, in its discretion, to discontinue the

 

 

eligibility of an agency under this Plan, as an automatic withdrawal from this Plan. See Section 9
below.

3. Methods of Payment and Amount of Contribution.

     An Eligible Agency will have three methods of payment, pursuant to subsections (a), (b) and
(c) of this Section 3, through which it may purchase shares of the Class A common stock under this
Plan. Subject to the provisions of Section 11(b), an Eligible Agency may elect any of the payment
methods individually or in combination. In each Subscription Period, as defined in Section 4, an
Eligible Agency may contribute an aggregate maximum of $12,000 toward the purchase of Class A
common stock under all payment methods combined (the “Maximum Amount”), subject to the limitations
set forth below:

     (a) An Eligible Agency may elect to purchase Class A common stock through deductions from its
monthly direct bill commission payments. Under this method, an Eligible Agency will direct the
Company to withhold no less than 1% and no more than 10% of the Eligible Agency’s direct bill
commission payments from the Eligible Agency’s direct bill commission payments; provided, however,
that the Company will withhold no more than $12,000 from direct bill commission payments during
each Subscription Period. Direct bill commission payments will mean the commissions earned and
that are actually available for payment in a monthly period to an Eligible Agency for personal and
commercial direct bill policies after all offsetting debits and credits are applied, as determined
solely from the Company’s records.

     (b) An Eligible Agency may elect to purchase Class A common stock during each October 1
through March 31 Subscription Period through a deduction from the contingent commission, if any,
payable to the Eligible Agency under the applicable agency contingent plan or its equivalent.
Under this method, an Eligible Agency will direct the Company to withhold a percentage of the
contingent commission subject to the Maximum Amount.

     (c) An Eligible Agency may elect to purchase Class A common stock through lump-sum payments to
the Company. Under this method, the Eligible Agency will pay to the Company a dollar amount in a
lump sum by the last day of the applicable Subscription Period. The amount of the lump sum payment
may not be less than $1,000 nor more than the Maximum Amount.

     At the end of each Subscription Period, the Company will total each Eligible Agency’s direct
bill commission payments, if any, and add such total to all lump-sum and contingent commission
payments, if any, made by such agency. If at any time during a Subscription Period an Eligible
Agency’s total payments exceed the Maximum Amount for that Subscription Period then, upon the
Eligible Agency’s request, the Company will return such excess amount to the Eligible Agency
without interest within a reasonable period. The Company will apply any such amount not returned
to the Eligible Agency to the purchase of

2

 

Class A common stock during the next Subscription Period without reducing the Maximum Amount
applicable to such Subscription Period.

4. Duration of This Plan and Subscription Periods.

     This Plan is effective as of October 1, 2011 through and including September 30, 2016. During
its term, this Plan will have ten semi-annual “Subscription Periods.” Each Subscription Period
will extend from October 1 through March 31 or from April 1 through September 30 of each year, with
the first Subscription Period beginning on October 1, 2011.

5. Enrollment and Enrollment Periods.

     “Enrollment Periods” are in effect from March 1 through March 30 and from September 1 through
September 30 of each year commencing with September 1, 2011. The Company will send an Eligible
Agency a Subscription Agreement prior to the beginning of the first Enrollment Period following
such agency’s designation as an Eligible Agency.

	 	(a)	 	An Eligible Agency that desires to subscribe for the purchase of Class A common stock
through withholding from direct bill commissions must return a duly executed and completed
Subscription Agreement during the first applicable Enrollment Period.
	 
	 	(b)	 	An Eligible Agency that wishes to make lump-sum purchases during a Subscription Period
will remit each lump-sum payment to the Company with a supplemental Subscription Agreement by the
last day of the applicable Subscription Period.
	 
	 	(c)	 	An Eligible Agency that wishes to make a purchase during a Subscription Period through
designation of a portion of its contingent commission under the agency contingent plan will file a
Subscription Agreement during the Enrollment Period applicable to that Subscription Period.

     Once enrolled, an Eligible Agency will continue to participate in this Plan for each
succeeding Subscription Period until it ceases to be an Eligible Agency or chooses to withdraw from
this Plan pursuant to Section 9. If an Eligible Agency desires to change its rate of contribution,
it may do so effective for the next Subscription Period by filing a new Subscription Agreement
during the Enrollment Period for the next Subscription Period.

6. Number of Shares To Be Offered.

     The total number of shares available under this Plan is 300,000 shares of the Class A common
stock. In the event all 300,000 shares of the Class A common stock are purchased

3

 

prior to the expiration of this Plan, the Company may terminate this Plan in accordance with
Section 13.

7. Subscription Price.

     The “Subscription Price” for each share of Class A common stock will be equal to 90% of the
average of the closing prices of the Class A common stock on the Nasdaq Global Select Market for
the last ten trading days of the applicable Subscription Period.

8. Purchase of Shares.

     The Company will maintain a “Plan Account” on behalf of each enrolled Eligible Agency. As of
the last day of each Subscription Period, the Company will credit the aggregate of (i) the amount
deducted from the Eligible Agency’s direct bill commission payments, (ii) the Eligible Agency’s
contingent commission withholdings and (iii) all of the Eligible Agency’s lump-sum payments, not to
exceed the Maximum Amount permitted pursuant to Section 3 of this Plan from all three payment
methods, to the Eligible Agency’s Plan Account. At such time, the Company will divide the amount
then contained in the Eligible Agency’s Plan Account by the Subscription Price for such
Subscription Period and credit each Plan Account with the number of whole shares that results. The
Company will carry forward any amount remaining in the Plan Account to the next Subscription Period
or, at the option of the Eligible Agency, return it to the Eligible Agency. Any amount so carried
forward will not increase the Maximum Amount applicable to such succeeding Subscription Period. If
the number of shares subscribed for during any Subscription Period exceeds the number of shares
available for sale under this Plan, the Company will allocate the remaining shares among all
Eligible Agencies in proportion to their aggregate Plan Account balances, exclusive of any amounts
carried forward as provided in Section 3 and this Section 8 of this Plan. The Company will issue
and deliver stock certificates to each Eligible Agency with respect to the shares it has purchased
under this Plan within a reasonable time thereafter.

9. Withdrawal from This Plan.

     An enrolled Eligible Agency may withdraw from this Plan at any time by giving written notice
of withdrawal signed by an authorized representative of the Eligible Agency to the Company.
Promptly after the time of withdrawal or the discontinuance of an Eligible Agency’s eligibility,
the Company will issue certificates representing any shares held under this Plan in the name of the
Eligible Agency and refund the amount of any cash credited to the Eligible Agency’s Plan Account
for the current Subscription Period without interest. If an Eligible Agency withdraws, such
Eligible Agency may not resubscribe until after the next full Subscription Period has elapsed, and
then only if the Company has redesignated such agency as an Eligible Agency.

4

 

10. Termination of Agency Status.

     The Company will treat termination of agency status for any reason as an automatic withdrawal
from this Plan pursuant to Section 9.

11. Assignment and Issuance of Shares.

     Except as expressly permitted by this Section 11, no Eligible Agency may assign its
subscription payments under this Plan or rights to subscribe under this Plan to any other person
(including its shareholders, partners or other principals), and any attempted assignment will be
void. Neither an Eligible Agency’s rights under this Plan nor shares held in an Eligible Agency’s
Plan Account may be transferred, pledged, hypothecated or assigned. All shares issued under this
Plan will be titled in the name of the Eligible Agency; provided, however, that an Eligible Agency
may, upon written request to the Company: (a) designate that the Company issue such shares to a
shareholder, partner, other principal or other licensed employee of such Eligible Agency, or (b)
designate that any retirement plan maintained by or for the benefit of such Eligible Agency or a
shareholder, partner, other principal or other licensed employee of such Eligible Agency may
purchase shares in lieu of such Eligible Agency through lump-sum payments made by the designee,
subject to the $12,000 Maximum Amount limitation set forth in Section 3, compliance with applicable
laws, including the Employee Retirement Income Security Act of 1974, as amended, and, if
applicable, payment by the Eligible Agency or its designee of any applicable transfer taxes and
satisfaction of the Company’s usual requirements for recognition of a transfer of Class A common
stock.

12. Adjustment of and Changes in the Class A Common Stock.

     In the event that the outstanding shares of the Class A common stock are hereafter increased
or decreased or changed into or exchanged for a different number or kind of shares or other
securities of the Company, or of another corporation, by reason of reorganization, merger,
consolidation, recapitalization, reclassification, stock split-up, stock dividend either in shares
of the Class A common stock or of another class of the Company’s stock, spin-off or combination of
shares, the Committee appointed pursuant to Section 14 of this Plan will make appropriate
adjustments in the aggregate number and kind of shares that are reserved for sale under this Plan.

13. Amendment or Discontinuance of This Plan.

     The board of directors of the Company will have the right to amend, modify or terminate this
Plan at any time without notice provided that the amendment, modification or termination of this
Plan does not adversely affect any participant’s existing rights.

5

 

14. Administration.

     A committee (the “Committee”) consisting of three persons the board of directors of the
Company has appointed from time to time will administer this Plan. The Committee may from time to
time adopt rules and regulations for carrying out this Plan. Any Committee interpretation or
construction of any provision of this Plan will be final and conclusive on all participants absent
contrary action by the board of directors. Any board of directors interpretation or construction of
any provision of this Plan will be final and conclusive on all participants.

15. Titles.

     Titles are provided in this Plan for convenience only and are not to serve as a basis for
interpretation or construction of this Plan.

16. Applicable Law.

     This Plan will be construed, administered and governed in all respects under the laws of the
Commonwealth of Pennsylvania and the United States of America.

6exv10w39

Exhibit 10.39

	 	 	[* *] Portions of the this exhibit have been omitted pursuant to a request for confidential
treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

PRODUCTS PURCHASE AGREEMENT

     THIS PRODUCTS PURCHASE AGREEMENT (this “Agreement”), is entered into and effective as
of the 16th day of February, 2011 (the “Effective Date”), by and between
Rockwell Medical Technologies, Inc., a Michigan corporation (“Rockwell”), and DaVita Inc.,
a Delaware corporation (“DaVita”) on behalf of itself and the DaVita Facilities (as defined
in Recital B). Capitalized terms used herein and not otherwise defined herein shall have the
meaning set forth in Article XVIII.

RECITALS

     A. Rockwell is in the business of manufacturing and selling dialysis products and supplies,
including the dialysis products and supplies set forth on Exhibit A attached hereto and
incorporated herein by this reference (each a, “Product”, and collectively, the
“Products”).

     B. DaVita owns (in whole or in part) and/or manages dialysis and vascular access facilities,
clinics or units located throughout the United States and its territories (each a, “DaVita
Facility”, and collectively, the “DaVita Facilities”).

     C. DaVita, on behalf of itself and the DaVita Facilities, desires to purchase and acquire from
Rockwell, and Rockwell desires to supply and sell to DaVita and the DaVita Facilities, the
Products, subject to all of the terms and conditions set forth in this Agreement.

     In consideration of the foregoing premises and mutual covenants, agreements, representations
and warranties contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound,
agree as follows:

ARTICLE I

PURCHASE AND SALE OF PRODUCTS AND REPORTS

     1.1 Sale and Purchase. During the Term (as defined in Section 2.2), and
subject to the terms and conditions of this Agreement, Rockwell will sell, supply, convey,
transfer, assign and deliver the Products to DaVita and the DaVita Facilities in such quantities as
DaVita and/or the DaVita Facilities may order from time to time.

     1.2 Product Commitment. DaVita covenants and agrees that at least [* *] of the DaVita
Facilities (the “Committed DaVita Facilities”) will use their best efforts to purchase all
of their requirements for acid concentrate (i.e. Dri-Sate® Dry Acid or RenalPureTM Liquid Acid) and
bicarbonate (i.e. RenalPureTM Bicarbonate Powder or SterilyteTM Liquid Bicarbonate) from Rockwell
each calendar year during the Term (the “Product Commitment”). [* *] Rockwell’s sole and
exclusive remedy against DaVita and the DaVita Facilities for any breach by the DaVita Committed
Facilities of the Product Commitment shall be to terminate this Agreement, and in such event
Rockwell shall not be entitled to any other relief or remedy whatsoever, including any monetary
damages, against DaVita and/or any of the DaVita Facilities. Rockwell understands and acknowledges
that the DaVita Facilities not included in the Committed DaVita Facilities (the “Non-Committed
DaVita Facilities”) have not promised or committed to purchase any particular quantity of any
of the Products or any particular percentage of

 

their requirements for items such as the Products, and that each of the Non-Committed DaVita
Facilities may purchase other products from other vendors and suppliers performing some or all of
the same functions as the Products.

     1.3 Monthly Reports. Each month during the Term, Rockwell shall deliver a report to
DaVita in accordance with DaVita’s specifications, which specifications will be given to Rockwell
by DaVita. Each monthly report, at a minimum, shall (a) show all purchases of the Products made by
each DaVita Facility by Product or Product categories, (b) include year-to-date purchase figures
for each DaVita Facility, and (c) include any other information reasonably requested by DaVita
relating to each DaVita Facility’s purchases of the Products pursuant to this Agreement.

     1.4 Notice of Changes to Product Labeling. If, at any time during the Term, Rockwell
or any applicable Governmental Authority determines that there must be an amendment, change,
revision and/or modification to the product labeling, safety information, and/or any other
information relating to any particular Product (a “Product Labeling Event”), Rockwell shall
within five (5) Business Days of any such Product Labeling Event, deliver a written notice to
DaVita which: (a) describes in reasonable detail any such Product Labeling Event, (b) explains in
reasonable detail the reasons and the causes for any such Product Labeling Event, and (c) includes
a copy of such amendment, change, revision and/or modification to the product labeling, safety
information, and/or any other information relating to any such particular Product (the “Product
Label Change Notice”). Rockwell shall respond to any questions, inquiries or requests for
additional information that DaVita or any DaVita Facility may have with respect to any Product
Label Change Notice and shall assist DaVita and the DaVita Facilities in understanding how, if at
all, any Product Labeling Event may affect or have an impact on DaVita’s or any DaVita Facilities’
use of the Products.

ARTICLE II

TERM AND TERMINATION

     2.1 Term. This Agreement shall commence on the Effective Date, and shall continue in
effect until December 31, 2013 (the “Initial Term”), unless sooner terminated in accordance
with the provisions of this Article II.

     2.2 Renewal. If, upon the expiration of the Initial Term, the parties hereto have not
negotiated, executed and delivered (a) a new agreement relating to the subject matter hereof or (b)
an extension of this Agreement, this Agreement shall continue until the earlier of either party
hereto providing ninety (90) days prior written notice of termination to the other party hereto or
the parties entering into a new agreement relating to the subject matter hereof or an extension of
this Agreement (the Initial Term, together with any such extension shall be referred to as the
“Term”).

     2.3 DaVita Termination Rights. This Agreement may be terminated by DaVita as follows:

     (a) Immediately in the event of a breach by Rockwell of any of its covenants and obligations
set forth in Articles VI or IX; or

     (b) Upon thirty (30) days prior written notice to Rockwell, in the event of a breach by
Rockwell of any representation, warranty, covenant or obligation of Rockwell contained in this
Agreement (other than the covenants and obligations set forth in Articles VI or
IX), and Rockwell fails to cure such breach within thirty (30) days following the date of
such notice; or

2

 

     (c) Immediately upon the occurrence of any of the following: (i) Rockwell files a voluntary
petition in bankruptcy seeking protection from creditors (a “Bankruptcy Filing”); or (ii)
Rockwell fails to contest an involuntary Bankruptcy Filing made against it or, despite contesting
such Bankruptcy Filing, fails to obtain its dismissal within sixty (60) days from its filing; or
(iii) a trustee or custodian is appointed for a substantial portion of or all of the assets of
Rockwell; or (iv) Rockwell fails to pay its debts as they become due or admits its inability to do
so (each of the foregoing, an “Insolvency Event”); or

     (d) Immediately in the event there is a change in Rockwell’s status which excludes it from
participation in any federal health care program, as defined under 42 U.S.C. § 1320a-7b(f).

     2.4 Rockwell Termination Rights. This Agreement may be terminated by Rockwell as
follows:

     (a) Immediately in the event of a breach by DaVita of any of its covenants and obligations set
forth in Article IX; or

     (b) Upon thirty (30) days prior written notice to DaVita, in the event of a breach by DaVita
of any representation, warranty, covenant or obligation of DaVita contained in this Agreement
(other than the covenants and obligations set forth in Article IX or Section 17.1),
and DaVita fails to cure such breach within thirty (30) days following the date of such notice; or

     (c) Immediately upon the occurrence of an Insolvency Event with respect to DaVita; or

     (d) Upon at least nine (9) months prior written notice to DaVita in the event that Rockwell
decides to either: [* *]

     (e) Upon sixty (60) days advance written notice to DaVita in the event of a breach by DaVita
of Section 17.1, and DaVita fails to cure such with breach within sixty (60) days following
the date of such notice; or

     (f) Immediately in the event there is a change in DaVita’s status which excludes it from
participation in any federal health care program, as defined under 42 U.S.C. § 1320a-7b(f).

     2.5 Effect of Termination. Termination of this Agreement will not release either
party hereto from any liability or obligation which, at the time of such termination, has already
accrued or which thereafter may accrue in respect to any act or omission of any party hereto prior
to such termination, nor will any such termination affect in any way the survival of any right,
duty or obligation of any party hereto, which is expressly stated elsewhere in this Agreement to
survive the termination.

ARTICLE III

PURCHASE PRICE AND OTHER PRICING COVENANTS

     3.1 Purchase Price. The purchase price for each Product is set forth on Exhibit
A (collectively, the “Purchase Price”). The Purchase Price includes [* *] to the
states set forth on Exhibit B attached hereto (the “Territory”). In the event that
DaVita and/or any DaVita Facility requires any Product to be shipped outside of the Territory,
DaVita and Rockwell shall [* *]. All orders for each Product by DaVita and/or any DaVita Facility
shall be subject to [* *] set forth on Exhibit C attached hereto. In the event that DaVita
and/or any DaVita Facility desires to order an amount of any Product [* *].

3

 

     3.2 Taxes. Rockwell covenants and agrees that neither DaVita nor any DaVita Facility
shall be liable for any taxes including any excise, gross receipts, gross earnings, gross value,
property, income taxes measured on Rockwell’s income, or other taxes, other than applicable sales
taxes, with respect to the purchase and sale of the Products.

     3.3 Pricing Covenant. Rockwell represents and warrants to DaVita that the Purchase
Price for each Product and all other terms of sale offered to DaVita and the DaVita Facilities for
each Product [* *].

     3.4 Price Increase. At any time on or after [* *], Rockwell may submit a written
notice to DaVita requesting a meeting with DaVita to discuss and negotiate in good faith possible
adjustments to the Purchase Price of any of the Products. The parties shall meet at a mutually
agreeable time and location within fifteen (15) days of such meeting request. During such meeting,
if Rockwell requests an increase to the Purchase Price of any Product, it shall deliver to DaVita
within five (5) days of such meeting or at such meeting, reasonably detailed documentation which
documents and indicates that [* *]. In the event the parties are not able to reach a mutually
agreeable adjustment to the Purchase Price of any of the Products for which Rockwell requested an
adjustment within thirty (30) days of the meeting, then either party hereto shall have the right to
terminate this Agreement upon ninety (90) days’ prior written notice to the other party hereto.

     3.5 Warrant. As further consideration for entering into this Agreement, Rockwell
agrees to provide DaVita with a warrant in the form attached to this Agreement as Exhibit E
(the “Warrant”) to purchase up to one hundred thousand (100,000) shares of Rockwell’s
common stock (the “Warrant Shares”). The Warrant Shares will have an exercise price equal
to one hundred ten percent (110%) of the closing bid price per share of Rockwell’s common stock as
quoted on NASDAQ on (a) the trading date immediately preceding the date on which this Agreement is
executed by the parties if such execution occurs at or before 4:00 p.m. Eastern time or (b) the
date on which this Agreement is executed by the parties if such execution occurs after 4:00 p.m.
Eastern time. The Warrant will expire at the earlier of (i) the close of business on the ninetieth
(90th) day immediately following the completion of the Initial Term or (ii) the
termination of this Agreement by Rockwell pursuant to Section 2.4. The Warrant will become
exercisable on the first day immediately following the end of the Initial Term and may be exercised
in whole or in part at any time after it becomes exercisable until its expiration by the submission
of an exercise notice in the form attached as an exhibit to the Warrant. If the Warrant expires
prior to the date it becomes exercisable, the Warrant shall not be exercisable. The Warrant Shares
issuable upon exercise of the Warrant shall bear a legend restricting transfer. The Warrants
Shares shall not be transferable and the Warrant shall bear a legend to that effect.

ARTICLE IV

PURCHASE ORDERS; DELIVERY; DEDICATED CUSTOMER SERVICE REPRESENTATIVE

     4.1 Purchase Orders and Delivery. Each Product shall be delivered by Rockwell to
DaVita and/or the DaVita Facilities pursuant to the terms of each purchase order submitted by
DaVita or any DaVita Facility. DaVita and/or the DaVita Facilities may submit an order for the
purchase of any of the Products via facsimile at [* *]. Rockwell shall provide accurate and
on-time deliveries of all orders placed, in accordance with any special instructions that may be
included in the purchase order. [* *].

     4.2 Dedicated Customer Service Representatives. Rockwell hereby agrees and covenants
that it shall provide DaVita with reasonable access to one or more dedicated customer service
representatives (each a, “Service Representative”) who shall be available to promptly
respond to and

4

 

address any issues that DaVita and/or any DaVita Facility may have with respect to any of the
Products (the “Customer Services”). Rockwell further agrees and covenants that each
Service Representative shall perform the Customer Services in the highest professional manner.

     4.3 Return Goods Policy. Rockwell hereby represents and warrants to DaVita that
attached hereto as Exhibit D is a true, correct and complete copy of Rockwell’s “Return
Goods Policy” (the “Return Goods Policy”). Notwithstanding anything to the contrary set
forth in the Return Goods Policy, DaVita or a DaVita Facility, as applicable, reserves the right to
inspect all Products and to reject any or all of the Products which are, in DaVita’s or a DaVita
Facility’s, as applicable, sole and absolute discretion, incorrectly shipped, defective, damaged,
contaminated or otherwise not in compliance with the warranties granted or assigned hereunder. Any
return pursuant to this Section 4.3 by DaVita and/or any DaVita Facility shall be sent back
to Rockwell, [* *]. DaVita or any DaVita Facility shall also have the right to return any of the
Products pursuant to the terms and conditions set forth in the Return Goods Policy that do not
conflict with this Section 4.3. Rockwell shall provide DaVita with at least thirty (30)
days prior written notice of any changes to the Return Goods Policy.

ARTICLE V

PAYMENT TERMS

     All purchases by DaVita or any DaVita Facility of Products pursuant to this Agreement shall be
paid on terms [* *]. DaVita or any DaVita Facility may withhold payment on the portion of any
invoice for which DaVita or such DaVita Facility, as applicable, has a bona fide dispute if it: (a)
pays all undisputed amounts, (b) notifies Rockwell of such invoice dispute, and (c) provides to
Rockwell a reconciliation of charges and any documentation necessary to support its claimed
adjustment. The parties hereto agree to use their commercially reasonable efforts to resolve any
such invoice dispute within thirty (30) days of Rockwell’s receipt of such invoice dispute notice
from DaVita or any DaVita Facility, as applicable.

ARTICLE VI

FAILURE TO SUPPLY

     In the event of Rockwell’s failure or inability to supply any Product within and for the time
period required by DaVita or any DaVita Facility, as applicable, including as a result of a force
majeure event (e.g. act of God, fire, casualty, flood, war, act of terrorism, strike, lockout,
labor trouble, failure of public utilities, injunction, epidemic, riot, insurrection or any other
circumstances beyond the reasonable control of the party asserting it) (a “Failure to Supply
Event”), Rockwell covenants and agrees that it shall (a) give notice as promptly as is
practicable under the circumstances to DaVita of such Failure to Supply Event, unless an order of a
regulatory agency or other action arising out of patient safety concerns requires the giving of
shorter notice; [* *]. Rockwell further covenants and agrees that during the period that a Failure
to Supply Event is occurring, none of the Committed DaVita Facilities shall be subject to the
Product Commitment.

ARTICLE VII

INVENTORY RESERVE COVENANTS

     Rockwell agrees and covenants to DaVita that it shall, at all times during the Term, to allow
for the continuous and uninterrupted supply of each of the Products to DaVita and the DaVita
Facilities to

5

 

enable the physicians at the DaVita Facilities to treat their patients: (a) maintain and
reserve for use exclusively by DaVita and the DaVita Facilities an amount of inventory of each of
the Products equal to [* *] and (b) have outstanding purchase orders with its suppliers for raw
materials and products in amount sufficient to allow Rockwell to manufacture an amount of each of
the Products equal to [* *] (the “Inventory Reserve Covenants”). [* *]. Rockwell and
DaVita agree to continuously work together and use their best efforts to increase and improve the
Inventory Reserve Covenants for each Product maintained by Rockwell for use exclusively by DaVita
and the DaVita Facilities.

ARTICLE VIII

ADDITIONAL PRODUCTS AND REPLACEMENT PRODUCTS

     8.1 Additional Products. Throughout the Term, Rockwell shall provide to DaVita and
the DaVita Facilities the right to purchase and/or lease all current or new products manufactured,
utilized, licensed, sold or distributed by Rockwell or any of its Affiliates (including products
and product lines acquired by Rockwell or any of its Affiliates as a result of an acquisition,
merger or other transaction involving Rockwell or any of its Affiliates) that are or that become
Commercially Available and which are not already covered by this Agreement or by any other
agreement, whether written or oral, between the parties hereto (such products are collectively
referred to as “Additional Products” and individually as an “Additional Product”).
Rockwell agrees to include DaVita in all of its and its Affiliates distributions of customer
announcements regarding Rockwell’s or its Affiliates’ Additional Products. The purchase price for
any such Additional Products shall be negotiated by the parties hereto in good faith and the agreed
upon purchase price shall be memorialized in writing as a supplement or amendment to this
Agreement. Rockwell covenants and agrees that it shall only make an offer for the sale of any
Additional Product(s) to DaVita’s Vice-President of Clinical Operations, Chief Medical Officer, or
Vice-President of Purchasing, and not to any DaVita Facility directly; provided
that the purchase of any Additional Product by DaVita or any DaVita Facility through a
Rockwell product catalog made generally available to the dialysis community shall not be a breach
by Rockwell of this Section 8.1. If Rockwell or any of its Affiliates acquires any
Additional Product(s) as a result of an acquisition, merger or other transaction involving Rockwell
or any of its Affiliates with a Person with which DaVita or a DaVita Facility, as applicable,
already has a purchase or rebate arrangement whether written or oral (a “Prior Agreement”),
Rockwell or such Affiliate covenants and agrees that it shall continue to abide by all of the terms
and conditions of such Prior Agreement or if DaVita requests, such Additional Product(s) shall be
included in this Agreement on terms to be negotiated and determined by the parties hereto as
provided in this Section 8.1.

     8.2 Replacement Products. If at anytime during the Term, Rockwell or any of its
Affiliates introduces a product or offering that is a replacement for an existing Product covered
by this Agreement, whether developed by Rockwell or any of its Affiliates or acquired by Rockwell
or any of its Affiliates in connection with any transaction (a “Replacement Product”),
Rockwell will allow (or will cause its Affiliate to allow) DaVita or any DaVita Facility, as
applicable, to purchase such Replacement Product at the same price as the Product it is replacing
or is ultimately intended to replace.

ARTICLE IX

CONFIDENTIAL INFORMATION COVENANTS

     9.1 Confidential Information.

6

 

     (a) No Disclosure of Confidential Information. The Non-Disclosing Party (as defined
in Article XVIII) agrees that in connection with the transactions contemplated by this
Agreement and the relationship of the parties hereto, it will have access to Confidential
Information of the Disclosing Party (as defined in Article XVIII) and that such
Confidential Information is vital, sensitive, confidential and proprietary to the Disclosing Party.
Therefore, the Non-Disclosing Party agrees that during the Term and for the longest time permitted
under applicable law after the Term, that it will (i) hold any Confidential Information delivered
or communicated to it by the Disclosing Party in the strictest confidence, including taking all
reasonable precautions to prevent the inadvertent disclosure of the Confidential Information to any
unauthorized third party or parties and (ii) not, at any time without the Disclosing Party’s
express written consent, which consent may be withheld by the Disclosing Party in its sole and
absolute discretion (A) disclose, reproduce, display, perform, record, broadcast, transmit,
distribute, modify, translate, combine with other information or materials, create derivative works
based on, exploit commercially or otherwise use the Confidential Information in any manner or
medium whatsoever, (B) disclose or publicize any of the Confidential Information or the terms of
this Agreement to any third party or parties, or (C) discuss with, or otherwise disclose or reveal
to, any third party or parties any information relating to the Disclosing Party’s business or the
Non-Disclosing Party’s duties or responsibilities to the Disclosing Party, regardless of whether
such information constitutes Confidential Information. Notwithstanding anything to the contrary
herein, the Non-Disclosing Party shall have the right to disclose any of the terms or provisions of
this Agreement upon any determination by the Non-Disclosing Party that such disclosure is necessary
in connection with the compliance by the Non-Disclosing Party with any legal requirement, including
applicable obligations and requirements pursuant to federal and state securities laws and listing
standards.

     (b) Retention and Destruction of Confidential Information. The Non-Disclosing Party
shall not take or retain any Confidential Information that is in written, email, computerized,
model, sample, or other form capable of physical delivery, upon or after the expiration or earlier
termination of this Agreement for any reason without the prior written consent of the Disclosing
Party, which consent may be withheld by the Disclosing Party in its sole and absolute discretion.
At any time upon the request of the Disclosing Party, the Non-Disclosing Party shall promptly
redeliver to the Disclosing Party or destroy all written materials containing or reflecting any
information contained in the Confidential Information (including all copies, extracts or other
reproductions) and agree to destroy all documents, memoranda, notes and other writings whatsoever
(including all copies, extracts or other reproductions), prepared by the Non-Disclosing Party based
on the information contained in the Confidential Information. Notwithstanding the return or
destruction of the Confidential Information, the Non-Disclosing Party will continue to abide by its
obligations of confidentiality and other obligations hereunder.

     (c) Exceptions to Confidential Information. Notwithstanding anything to the contrary
herein, Confidential Information shall not include any information that (i) was already known to
the Non-Disclosing Party at the time of disclosure by the Disclosing Party free of any restriction,
(ii) is generally available to the public or becomes publicly known through no wrongful act of the
Non-Disclosing Party, or (iii) is received by the Non-Disclosing Party from a third-party who has a
legal right to provide such information to the Non-Disclosing Party.

     (d) Use of Trademarks and Other Intellectual Property. Each party hereto agrees not
to internally or externally use, release, publish or distribute any materials or information
(including advertising and promotional materials) containing the names, tradenames, or trademarks
or other intellectual property right of the other party hereto without the express prior written
consent of such other party hereto.

7

 

     (e) Disclosures of Confidential Information Required By Law. In the event that the
Non-Disclosing Party is required by law (by oral questions, interrogatories, request for
information or documents, subpoena, civil investigative demand or any other similar process) to
disclose any Confidential Information, the Non-Disclosing Party agrees to provide the Disclosing
Party with prompt written notice of such request(s) (but in no event later than five (5) days after
the receipt of such request(s)) and shall consult with the Disclosing Party as to the advisability
of taking legally advisable steps to resist or narrow such request(s). Notwithstanding the
foregoing, if disclosure of such Confidential Information is required by law, the Non-Disclosing
Party will (i) furnish only that portion of the Confidential Information which, in the reasonable
opinion of the Non-Disclosing Party’s counsel, after consultation with the Disclosing Party’s
counsel, it is legally obligated to disclose, and (ii) use its best efforts to obtain an order or
other reliable assurances that confidential, non-public treatment will be accorded to all such
disclosed Confidential Information.

     (f) Employees, Agents, Representatives, Etc. For purposes of this Section
9.1, any Confidential Information received by any director, officer, member, manager, partner,
employee, agent, subcontractor, advisor or representative of the Non-Disclosing Party pursuant to
the terms and conditions of this Agreement shall be deemed received by the Non-Disclosing Party and
any breach by such persons of this Section 9.1 shall be deemed a breach by the
Non-Disclosing Party of this Agreement.

     9.2 Enforcement. The Non-Disclosing Party expressly acknowledges and agrees that the
restrictions contained herein are reasonable in terms of duration and scope restrictions and are
necessary to protect the Confidential Information and the goodwill of the business of the
Disclosing Party, and the Non-Disclosing Party agrees that it shall not challenge the validity or
enforceability of the restrictions contained herein. The Non-Disclosing Party agrees that money
damages would not be an adequate remedy for any breach of this Article IX. Therefore, in
the event of a breach or threatened breach of the provisions of this Article IX by the
Non-Disclosing Party, the Disclosing Party may, in addition to other rights and remedies existing
in its favor, apply to any court of competent jurisdiction for specific performance and/or
injunctive or other relief in order to enforce or prevent any violation of the provisions of this
Article IX (without proving monetary damages or posting a bond or other security).

ARTICLE X

REPRESENTATIONS AND WARRANTIES OF ROCKWELL

     Rockwell hereby represents and warrants to DaVita as follows:

     10.1 Standing and Authority. Rockwell has the requisite corporate power, right and
authority to enter into this Agreement and to consummate the transactions contemplated hereby.
Rockwell’s execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby have been duly and validly authorized by all necessary corporate action on the
part of Rockwell.

     10.2 Execution; Delivery; Binding Effect. This Agreement has been duly executed and
delivered by Rockwell, and constitutes the legal, valid and binding obligation of Rockwell,
enforceable against Rockwell in accordance with its terms.

     10.3 No Conflicts. Neither the execution, delivery or performance of this Agreement
by Rockwell nor the consummation of the transactions contemplated in this Agreement, shall (a)
conflict with, contravene or result in a breach of any statute or administrative regulation, or of
any law, rule, regulation, ordinance, order, writ, injunction, judgment, or decree of any
Governmental Authority or of any arbitration award to which Rockwell is a party or by which any of
the properties or assets of Rockwell are or may be bound; or (b) conflict with, contravene or
violate any agreement, understanding

8

 

or arrangement to which Rockwell is a party or by which any of the properties or assets of
Rockwell are or may be bound.

     10.4 Title. Rockwell possesses good and marketable title to all of the Products free
and clear of any and all liens, mortgages, charges, security interests, pledges or other
encumbrances or adverse claims of any nature, whether arising by agreement, operation of law or
otherwise (collectively, “Liens”). Rockwell has the right to convey and in connection with
the transactions contemplated by this Agreement will convey to DaVita and/or the DaVita Facilities,
as applicable, good and marketable title to all of the Products acquired hereunder, free and clear
of any and all Liens.

     10.5 Licenses, Permits, and Compliance with Laws. Rockwell has all rights, licenses,
permits and consents necessary to sell the Products to DaVita and the DaVita Facilities and to
perform its obligations hereunder during the Term. Rockwell is and has at all times been in and
during the Term shall be in compliance with all federal, state and local laws, statutes, rules, and
regulations applicable to its business and the performance of its obligations under this Agreement.
No Product delivered hereunder during the Term is or will be adulterated or misbranded within the
meaning of the FFDCA, or within the meaning of any applicable state or municipal law, or is or will
be a product which may not be introduced into interstate commerce. During the Term, Rockwell shall
immediately inform DaVita following its receipt of any information which states that the integrity
or legal status of any Product provided hereunder has been called into question by any retailer,
wholesaler, or state or federal authority, or that any Product sold to DaVita or any DaVita
Facility hereunder is suspected of being counterfeit, stolen, adulterated, misbranded or otherwise
an unlawful product and shall provide DaVita with prompt written confirmation of any such event,
including copies of any and all documents related thereto. DaVita’s and the DaVita Facilities’ use
of the Products in accordance with their intended use shall not infringe upon any ownership rights
of any other Person or upon any patent, copyright, trademark, or other intellectual property or
proprietary right or trade secret of any third party.

     10.6 Products. Each Product purchased during the Term (a) is and shall be
manufactured in accordance with its packaging, (b) is and shall be manufactured, handled, stored
and transported in accordance with all applicable United States, state and local laws and
regulations pertaining thereto, including to the extent applicable, the FFDCA and implementing
regulations and FDA approved Good Manufacturing Practices, (c) meets all specifications for
effectiveness and safety as required by the FDA, (d) is fit for the indications described in its
labeling, and (e) is labeled in compliance with all applicable laws. Each Product is and will (i)
be of the kind and quantity specified herein, (ii) be of safe and merchantable quality, (iii) be
free of defects in design, materials, manufacture or workmanship when delivered, (iv) [* *] (v)
conform to its specifications as written or published, unless otherwise agreed to by the parties
hereto. In the event any Product, or any component of a Product, is not manufactured by Rockwell,
Rockwell hereby assigns or agrees to assign (to the extent assignable) to DaVita all such
manufacturer warranties, copies of which shall be provided by Rockwell to DaVita upon request.

     10.7 Expired Product. Rockwell will use its best efforts not to ship to DaVita or any
DaVita Facility expired Product [* *], unless agreed to in writing by DaVita. In the event
Rockwell ships to DaVita or any DaVita Facility expired Product [* *], DaVita shall have the right
to return such Product to Rockwell at Rockwell’s sole cost and expense.

     10.8 Health Care Programs. Rockwell is not currently (a) named on any of the following
lists (i) HHS/OIG List of Excluded Individuals/Entities, (ii) GSA List of Parties Excluded from
Federal Programs or (iii) OFAC “SDN and Blocked Individuals” and (b) under investigation or
otherwise aware

9

 

of any circumstances which would result in Rockwell being excluded from participation in any
federal health care program, as defined under 42 U.S.C. §1320a-7b(f).

All warranties granted or assigned under this Article X will continue in full force and
effect notwithstanding transfer of title to any Product to or by DaVita or any DaVita Facility to
any other DaVita Facility. All warranties granted under this Agreement shall survive inspection,
acceptance and payment of the Products.

ARTICLE XI

REPRESENTATIONS AND WARRANTIES OF DAVITA

     DaVita hereby represents and warrants to Rockwell as follows:

     11.1 Standing and Authority. DaVita has the requisite corporate power, right and
authority to enter into this Agreement and to consummate the transactions contemplated hereby.
DaVita’s execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby have been duly and validly authorized by all necessary corporate action on the
part of DaVita.

     11.2 Execution; Delivery; Binding Effect. This Agreement has been duly executed and
delivered by DaVita, and constitutes the legal, valid and binding obligation of DaVita, enforceable
against DaVita in accordance with its terms.

     11.3 No Conflicts. Neither the execution, delivery or performance of this Agreement
by DaVita nor the consummation of the transactions contemplated in this Agreement, shall (a)
conflict with, contravene or result in a breach of any statute or administrative regulation, or of
any law, rule, regulation, ordinance, order, writ, injunction, judgment, decree of any Governmental
Authority or of any arbitration award to which DaVita is a party or by which any of the properties
or assets of DaVita are or may be bound; or (b) conflict with, contravene or violate any provision
of any agreement, understanding or arrangement to which DaVita is a party or by which any of the
properties or assets of DaVita are or may be bound.

     11.4 Compliance with Laws. DaVita has all rights, licenses, permits and consents
necessary to perform its obligations hereunder during the Term. DaVita is and has at all times
been in and during the Term shall be in compliance with all federal, state and local laws,
statutes, rules, and regulations applicable to its business and the performance of its obligations
under this Agreement.

     11.5 Health Care Programs. DaVita is not currently (a) named on any of the following
lists (i) HHS/OIG List of Excluded Individuals/Entities, (ii) GSA List of Parties Excluded from
Federal Programs or (iii) OFAC “SDN and Blocked Individuals” and (b) under investigation or
otherwise aware of any circumstances which would result in DaVita being excluded from participation
in any federal health care program, as defined under 42 U.S.C. §1320a-7b(f).

ARTICLE XII

INDEMNIFICATION AND INSURANCE

     12.1 Indemnification of DaVita. Rockwell agrees to defend, indemnify and hold DaVita,
its Affiliates and the DaVita Facilities and each of their respective directors, officers, members,
managers, partners, employees and agents (collectively, the “DaVita Indemnitees”) harmless
from and against any and all causes of action (at law or in equity), actions, claims, costs, suits,
liabilities, judgments,

10

 

settlements, demands, losses, damages, proceedings and/or expenses of all kinds (including
reasonable attorneys’ fees, witnesses’ fees, investigation expenses, and any other expenses
incident thereto) (collectively, “Losses”) that the DaVita Indemnitees may sustain or incur
as a result of: (a) any breach of any representation or warranty made by Rockwell in this Agreement
or in materials furnished by Rockwell for DaVita’s and the DaVita Facilities’ use; (b) any breach
by Rockwell of any of its covenants or obligations in this Agreement; (c) the use of any Product by
DaVita and/or any DaVita Facility in accordance with any such Products’ labeling and instructions
for use; (d) any defect in the design or manufacture of any Product (including claims for property
damage, loss of life, and bodily injury); (e) any Recall (as defined in Article XIII) with
respect to any Product; or (f) any negligent, reckless, wanton, malicious or tortious conduct by
Rockwell in connection with the transactions contemplated by this Agreement. Notwithstanding the
foregoing, in no event shall Rockwell have an obligation to defend, indemnify or hold any of the
DaVita Indemnitees harmless hereunder to the extent any such Losses were caused by the sole
negligence or willful misconduct of any such DaVita Indemnitees.

     12.2 Indemnification of Rockwell. DaVita agrees to defend, indemnify and hold
Rockwell and its Affiliates and each of their respective directors, officers, members, managers,
partners, employees and agents (collectively, the “Rockwell Indemnitees”) harmless from and
against any and all Losses that the Rockwell Indemnitees may sustain or incur as a result of: (a)
any breach of any representation or warranty made by DaVita in this Agreement; (b) any breach by
DaVita of any of its covenants or obligations in this Agreement; (c) the use of any Product by
DaVita and/or any DaVita Facility not in accordance with any such Products’ labeling and
instructions for use; (d) any DaVita Facilities’ negligence or misconduct in the “Administration”
of a Product to its patients; or (e) any negligent, reckless, wanton, malicious or tortious conduct
by DaVita in connection with the transactions contemplated by this Agreement. For purposes of this
Section 12.2, the “Administration” of a Product by a DaVita Facility shall mean the
dispensing and handling by such DaVita Facility and its employees of such Product and the actual
administration of such Product to patients by such DaVita Facility and its employees, but shall
exclude physician prescriptions of such Product to patients. Notwithstanding the foregoing, in no
event shall DaVita have an obligation to defend, indemnify or hold any of the Rockwell Indemnitees
harmless hereunder to the extent any such Losses were caused by the sole negligence or willful
misconduct of any such Rockwell Indemnitees.

     12.3 Indemnification Procedure for Third Party Claims. If any DaVita Indemnitee or
any Rockwell Indemnitee entitled to indemnification under this Article XII (the
“Indemnified Party”) receives notice of the assertion of any claim, or the commencement of
any suit, action or proceeding by any Person who is not a party hereto or an Affiliate of a party
hereto (a “Third Party Claim”) against such Indemnified Party, the Indemnified Party shall
give written notice regarding such Third Party Claim to the party hereto that is required to
provide indemnification under this Article XII (the “Indemnifying Party”) within
thirty (30) days after learning of such Third Party Claim. The Indemnifying Party shall have the
right, upon written notice to the Indemnified Party (the “Defense Notice”) within thirty
(30) days after receipt from the Indemnified Party of notice of such Third Party Claim, which
Defense Notice by the Indemnifying Party shall specify the counsel it will appoint to defend such
Third Party Claim (“Defense Counsel”), to conduct at its expense the defense against such
Third Party Claim in its own name, or if necessary in the name of the Indemnified Party;
provided, however, that: (a) the Indemnified Party shall have the right to approve
the Defense Counsel, which approval shall not be unreasonably withheld, conditioned or delayed by
the Indemnified Party and (b) as a condition precedent to the Indemnifying Party’s right to assume
control of such defense, the Indemnifying Party must first enter into an agreement with the
Indemnified Party (in form and substance reasonably satisfactory to the Indemnified Party) pursuant
to which the Indemnifying Party agrees to be fully responsible for any and all Losses relating to
such suit Third Party Claim and unconditionally guarantees the payment and performance of any and
all Losses which may arise with respect to such Third Party Claim, subject to the terms and conditions set

11

 

forth in this Section 12. The
Indemnifying Party shall not have the right to assume control of, but may participate in, and the
Indemnified Party shall have the sole right to assume control of any Third Party Claim which: (i)
seeks a temporary restraining order, a preliminary or permanent injunction or specific performance
against the Indemnified Party, (ii) involves criminal or quasi-criminal allegations against the
Indemnified Party, (iii) if unsuccessful would set a precedent that would materially interfere
with, or have a material adverse effect on, the business or financial condition of the Indemnified
Party, or (iv) imposes liability in the part of the Indemnified Party for which the Indemnified
Party is not entitled to indemnification under this Article XII. If the Indemnifying Party
is permitted to assume and control the defense of any Third Party Claim and elects to do so, the
Indemnified Party shall have the right to employ counsel separate from counsel employed by the
Indemnifying Party in any such Third Party Claim and to participate in the defense thereof, but the
fees and expenses of such counsel employed by the Indemnified Party shall be at the expense of the
Indemnified Party unless (A) the employment thereof has been specifically authorized by the
Indemnifying Party in writing, (V) the Indemnified Party has been advised by counsel that a
reasonable likelihood exists of a conflict of interest between the Indemnifying Party and the
Indemnified Party, or (C) the Indemnifying Party has failed to assume the defense and employ
counsel, in which case the fees and expenses of the Indemnified Party’s counsel shall be paid by
the Indemnifying Party. No Indemnifying Party shall consent to the entry of any judgment or enter
into any settlement of any Third Party Claim without the prior written consent of the Indemnified
Party if (w) such judgment or settlement would lead to liability or create any financial or other
obligation on the part of the Indemnified Party for which the Indemnified Party is not entitled to
indemnification hereunder, (x) such judgment or settlement would result in the finding or admission
of any violation of any federal, state or local law, statute, ordinance or regulation, (y) such
judgment or settlement does not include as an unconditional term thereof the giving by each
claimant or plaintiff to each Indemnified Party of a release from all liability in respect to such
Third Party Claim, or (z) as a result of such judgment or settlement, injunctive or other equitable
relief would be imposed against the Indemnified Party. In the event that the Indemnifying Party
fails to give the Defense Notice within thirty (30) days of receiving notice of such Third Party
Claim from the Indemnified Party, it shall be deemed to have elected not to conduct the defense of
such Third Party Claim, or in the event the Indemnifying Party does deliver a Defense Notice within
thirty (30) days of receiving notice of such Third Party Claim from the Indemnified Party and
thereby elects to not conduct the defense of such Third Party Claim, then in either such event the
Indemnified Party shall have the right to conduct and control the defense of such Third Party Claim
in good faith and to compromise and settle such Third Party Claim or consent to the entry of a
judgment of such Third Party Claim in good faith without the prior consent of the Indemnifying
Party. A failure by the Indemnified Party to give timely, complete or accurate notice as provided
in this Section 12.3 will not affect the rights or obligations of the Indemnifying Party
except and only to the extent that, as a result of such failure, the Indemnifying Party entitled to
receive such notice was deprived of its right to recover any payment under its applicable insurance
coverage or was otherwise directly and materially damaged as a result of such failure to give
timely notice.

     12.4 Indemnification Procedure for Direct Claims. In the event the Indemnified Party
should have a claim against the Indemnifying Party hereunder which does not involve a Third Party
Claim (a “Direct Claim”), such Indemnified Party shall transmit to the Indemnifying Party a
written notice (the “Direct Indemnification Notice”) containing an estimate of the amount
of damages attributable to such Direct Claim and the basis of such Indemnified Party’s request for
indemnification under this Article XII within thirty (30) days after learning of such
Direct Claim. If the Indemnifying Party does not notify such Indemnified Party in writing within
thirty (30) days from its receipt of the Direct Indemnification Notice that the Indemnifying Party
disputes the Direct Claim set forth in such Direct Indemnification Notice, the Direct Claim
specified by such Indemnified Party in such Direct Indemnification Notice shall be deemed a
liability of the Indemnifying Party hereunder. If the Indemnifying Party has timely disputed the Direct

12

 

Claim set forth in
such Direct Indemnification Notice, as provided in this Section 12.4, such Direct Claim set
forth in such Direct Indemnification Notice shall be resolved by litigation.

     12.5 Insurance. Each party hereto agrees that it shall secure and maintain in full
force and effect throughout the Term (and following termination, to cover any claims or liabilities
arising from this Agreement) commercial general liability insurance, which includes contractual
liability coverage, product liability (only in the case of Rockwell) and workers’ compensation
insurance, to cover any claims or liabilities arising from this Agreement. Such commercial general
liability insurance shall be in an amount reasonably satisfactory to the other party hereto. Any
limits on either party’s insurance coverage shall not be construed to create a limit on its
liability with respect to any of its obligations hereunder. Each party hereto shall name the other
party as an additional insured on such party’s commercial general liability insurance policy. Such
commercial general liability insurance policy shall provide at least thirty (30) days prior written
notice to the other party hereto of the cancellation, non-renewal or substantial modification
thereof. Each party hereto shall supply certificates of insurance to the other party hereto upon
the other party’s request.

ARTICLE XIII

RECALL

     In the event the FDA initiates a mandatory recall (i.e. the correction or removal of a
Product) or Rockwell believes in its sole discretion that it may be necessary to conduct a recall
(i.e. the correction or removal of a Product), field market withdrawal, stock recovery, or other
similar action with respect to any of the Products (a “Recall”), Rockwell shall immediately
notify DaVita of such Recall. The parties hereto agree that the final decision as to and control
of the handling of any Recall shall be in Rockwell’s sole discretion; provided that
Rockwell conducts any such Recall in accordance with any and all applicable legal requirements and
general guidance issued by the FDA. In the event that Rockwell does not conduct a Recall, clearly
and without dispute, in accordance with all applicable legal requirements and general guidance
issued by the FDA, [* *]. DaVita shall provide all reasonable assistance requested by Rockwell in
connection with a Recall. In the event of a Recall with respect to any Product, Rockwell shall
reimburse DaVita for: [* *]. DaVita and Rockwell shall maintain records of all sales of the
Products and customers who received such Products so as to enable Rockwell to adequately administer
a Recall with respect to any of the Products in accordance with applicable legal requirements and
general guidance issued by the FDA. In the event of a Recall, neither party hereto shall make any
statement to the press or public concerning such Recall without first notifying the other party
hereto and obtaining such other party’s prior written approval of any such statement, which
approval shall not be unreasonably withheld, conditioned or delayed. Any return by DaVita or any
DaVita Facility pursuant to this Article XIII shall be sent back to Rockwell, [* *].

ARTICLE XIV

OPEN RECORDS AND DISCOUNTS

     14.1 Open Records. To the extent required by §1861(v)(1)(I) of the Social Security
Act, the parties hereto will allow the U.S. Department of Health and Human Services, the U.S.
Comptroller General, and their duly authorized representatives, access to this Agreement and any
records necessary to verify the nature and extent of costs incurred pursuant to this Agreement
during the Term and for four (4) years following the last date any Products are furnished by
Rockwell to DaVita or any DaVita Facility under this Agreement. If Rockwell carries out its
obligations under this Agreement through a subcontract
worth Ten Thousand Dollars ($10,000) or more over a twelve (12) month period with a related

13

 

organization, the subcontract shall also contain an access clause to permit access by the U.S.
Department of Health and Human Services, the U.S. Comptroller General, and their duly authorized
representatives to the related organization’s books and records. Nothing in this Section
14.1 is intended to waive any right either party hereto may have under any applicable laws or
regulations to retain in confidence information included in records so requested.

     14.2 Discounts. Any discounts, rebates, incentives, and/or other reductions in price
issued by Rockwell to DaVita and/or any DaVita Facility under this Agreement may constitute a
discount within the meaning of 42 U.S.C. §1320a-7b(b)(3)(A). DaVita and the DaVita Facilities may
have an obligation to properly disclose and appropriately reflect any such discounts, rebates,
incentives and/or other reductions in price to any state or federal program that provides cost or
charge based reimbursement to DaVita and/or any such DaVita Facility for the items to which such
discounts, rebates, incentives and/or other reductions in price apply. In order to assist DaVita’s
and the DaVita Facilities’ compliance with any such obligations, Rockwell agrees that it shall
fully and accurately report all discounts, rebates, incentives and/or other reductions in price on
the invoices, coupons or statements submitted to DaVita or any DaVita Facility and inform DaVita
and/or any such DaVita Facility of their obligations to report such discounts, rebates, incentives
and/or other reductions in price. In the event the value of any discounts, rebates, incentives
and/or other reductions in price are not known at the time of sale, Rockwell shall fully and
accurately report the existence of such discounts, rebates, incentives and/or other reductions in
price on the invoices, coupons or statements submitted to DaVita and/or any DaVita Facility, inform
DaVita and/or any DaVita Facility of their obligations to report such discounts, rebates,
incentives and/or other reductions in price, and when the value of such discounts, rebates,
incentives and/or other reductions in price becomes known, provide DaVita and/or any DaVita
Facility with documentation of the calculation of such discounts, rebates, incentives and/or other
reductions in price and identifying the specific Products purchased to which such discounts,
rebates, incentives and/or other reductions in price will be applied. Rockwell shall also provide
to DaVita and/or any DaVita Facility any other information that DaVita and/or any DaVita Facility
may request that is necessary for them to obtain in order to comply with any such obligations, and
Rockwell shall refrain from doing anything which would impede DaVita and/or any DaVita Facility
from meeting their obligations under this Section 14.2 or any Medicare regulation.

ARTICLE XV

ACCESS AND POLICIES AND PROCEDURES

     Rockwell acknowledges and agrees that (a) DaVita has informed Rockwell that copies of all of
DaVita’s applicable vendor relations policies and procedures (the “Policies and
Procedures”) that will be in effect during the Term will be available for viewing by Rockwell
during the Term by going to: http://www.davita.com/about/company/?id=3902 and (b)
Rockwell shall abide by all such Policies and Procedures during the Term. Rockwell understands and
agrees that it must obtain DaVita’s prior written approval of all proposed educational, marketing
and promotional materials and of all presentations made by Rockwell relating to any of the Products
or any other Rockwell products, which approval may only be given in writing by DaVita’s Vice
President, Clinical Operations or his authorized representative. DaVita’s Vice President, Clinical
Operations or his authorized representative agrees to notify Rockwell of his decision within ten
(10) Business Days following receipt of such request; otherwise, such request will be deemed
denied. No personnel or agent of Rockwell shall be permitted to access any DaVita Facility without
the prior written consent of DaVita’s Vice President, Clinical Operations or his authorized
representative.

14

 

ARTICLE XVI

AUDIT

     If DaVita disagrees with any computation or statement delivered by Rockwell to DaVita or any
DaVita Facility under this Agreement, DaVita may, within thirty (30) days after the receipt of such
computation or statement, audit any such computation or statement. DaVita shall conduct any such
audit during such times as may be mutually agreed to by the parties hereto. In the event that
DaVita’s audit results in a number different from that set forth in the computation or statement
delivered by Rockwell to DaVita or any DaVita Facility, DaVita shall deliver a written notice (an
“Objection Notice”) to Rockwell setting forth in reasonable detail any and all items of
disagreement related to such computation or statement. If DaVita does not deliver an Objection
Notice within such thirty (30) day period, the calculations set forth in any such computation or
statement shall be deemed final, conclusive and binding on the parties hereto. Rockwell and DaVita
will use their commercially reasonable efforts to resolve any disagreements relating to any
computation or statement, but if they do not obtain a final resolution within twenty (20) days
after Rockwell has received the Objection Notice, then either Rockwell or DaVita may refer the
items in dispute to a nationally recognized firm of independent public accounts as to which DaVita
and Rockwell mutually agree (the “Firm”), to resolve any remaining disagreements. Rockwell
and DaVita will direct the Firm to render a determination within twenty (20) days of its retention,
and Rockwell and DaVita and their respective agents and employees will cooperate with the Firm
during its engagement. The determination of the Firm will be conclusive and binding upon DaVita
and Rockwell, and DaVita or Rockwell, as applicable, will make any payment owed to other party
hereto within five (5) Business Days of the Firm’s determination. The Firm shall execute a
confidentiality agreement in a form reasonably acceptable to Rockwell and DaVita. [* *].

ARTICLE XVII

ADDITIONAL ACKNOWLEDGEMENTS AND AGREEMENTS OF THE PARTIES

     17.1 Discontinuation Event. DaVita agrees that: (a) in the event a Committed DaVita
Facility intends on discontinuing its purchase of the Products from Rockwell (a
“Discontinuation Event”), it shall [* *]. DaVita further agrees that in the event a
Discontinuation Event occurs as to multiple Committed DaVita Facilities in a geographic county,
group of nearby counties, or subdivisions of a county (a “Market”), it shall use its
commercially reasonable efforts to implement such Discontinuation Event as to such Committed DaVita
Facilities in such Market in a manner which assists Rockwell in minimizing the negative effect it
would experience as a result of such Discontinuation Event. In the event of a breach by DaVita of
the provisions of this Section 17.1, Rockwell’s sole and exclusive remedy shall be to
terminate this Agreement pursuant to Section 2.5(e).

     17.2 Business Model Change. Rockwell agree to [* *] and to use commercially
reasonable efforts to [* *]. DaVita acknowledges that in the event Rockwell wishes to [* *], it
will use its commercially reasonable efforts to [* *]; provided that if DaVita uses
its commercially reasonable efforts to [* *], DaVita shall have no liability whatsoever to
Rockwell, including any direct, indirect, consequential, exemplary or punitive damages, [* *].

     17.3 Mixer Training. Rockwell agrees to furnish, [* *], complete and appropriate
training regarding the use and maintenance of the Dri-Sate® Acid Mixer used for mixing Dri-Sate®
Dry Acid and CitraPure® Dry Acid, to such number of personnel of DaVita and the DaVita Facilities
as DaVita shall designate. [* *].

     17.4 Bicarbonate Mixer. Upon mutual written agreement between the parties hereto,
Rockwell will [* *].

15

 

ARTICLE XVIII

CERTAIN DEFINED TERMS

     The following terms as used herein have the following meaning:

     “Affiliate” means, with respect to a Person, any Person that, directly or indirectly,
through one or more intermediaries, controls, is controlled by, or is under common control with,
such Person.

     “Business Day” means a day other than Saturday, Sunday or a public holiday on which
banks are authorized or required to be closed under the laws of the State of California.

     “Commercially Available” means any product that is approved by the FDA and
manufactured, utilized, sold or distributed anywhere in the United States by Rockwell and/or any of
its Affiliates.

     “Confidential Information” means information not generally known outside the
disclosing party and/or any of its Affiliates (collectively, the “Disclosing Party”)
(unless as a result of a breach of any of the non-disclosing party’s and/or any of its
Affiliates’(collectively, the “Non-Disclosing Party’s”) obligations imposed by this
Agreement) or which is identified as confidential by the Disclosing Party to the Non-Disclosing
Party concerning the Disclosing Party’s business and technical information, whether in written,
computerized, oral, tangible or intangible or other form, including: (a) the terms and provisions
of this Agreement, (b) any and all trade secrets concerning the business, customers and affairs of
the Disclosing Party, product specifications, data, know-how, formulae, compositions, processes,
designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current and
planned research and development, current and planned manufacturing and distribution methods and
processes, customer lists, current and anticipated customer requirements, price lists, market
studies, business plans, clinical practices and patient protocols, computer software and programs
(including object code and source code), database technologies, systems, improvements, devices,
discoveries, concepts, methods, and information of the Disclosing Party and any other information
of the Disclosing Party, however documented, that is a trade secret under applicable law, (c) any
and all information concerning the business and affairs of the Disclosing Party, including
historical financial statements, financial projections and budgets, rebates, discounts, payment
terms, pricing, historical and projected sales, capital spending budgets and plans, contractual
arrangements, the names and background of key personnel, contractors, agents, customers, suppliers
and potential suppliers, personnel training and techniques and materials, purchasing methods and
techniques, however documented, (d) the names and addresses, records and charts and any other
information concerning the Disclosing Party’s patients, and (e) any and all notes, analysis
compilations, studies, summaries and other materials prepared by or for the Disclosing Party
containing or based, in whole or in part, upon any information included in the foregoing.

     “FDA” means the United States Food and Drug Administration and any successor thereto.

     “FFDCA” means the United States Federal Food, Drug and Cosmetic Act of 1938 and all
regulations promulgated thereunder.

     “Governmental Authority” means any multi-national, national, state, provincial, local,
governmental, judicial, public, quasi-public, administrative, regulatory or self-regulatory
authority, agency, commission, board, organization or instrumentality.

     “Person” means any individual or any group of individuals or any general partnership,
limited partnership, limited liability partnership, limited liability company, professional limited
liability company, corporation, joint venture, trust, business trust, cooperative or association or
any other

16

 

organization that is not a natural person and any combination of any such entity or
organization and any natural persons acting in concert, and the heirs, executors, administrators,
legal representatives, successors and assigns of any “person” where the context so permits.

     “Sale of DaVita” means any transaction or series of transactions pursuant to which any
Person or group of related Persons in the aggregate acquire(s) (a) securities of DaVita possessing
the voting power to elect a majority of DaVita’s board of directors (whether by merger,
consolidation, reorganization, combination, sale or transfer of DaVita’s securities, securityholder
or voting agreement, proxy, power of attorney or otherwise) or (b) all or substantially all of
DaVita’s assets.

     “Sale of Rockwell” means any transaction or series of transactions pursuant to which
any Person or group of related Persons in the aggregate acquire(s) (a) securities of Rockwell
possessing the voting power to elect a majority of Rockwell’s board of directors (whether by
merger, consolidation, reorganization, combination, sale or transfer of Rockwell’s securities,
securityholder or voting agreement, proxy, power of attorney or otherwise) or (b) all or
substantially all of Rockwell’s assets.

     “Transfer” means (a) any Sale of Rockwell, (b) Sale of DaVita, or (c) any sale,
transfer, assignment, pledge, mortgage, exchange, hypothecation, grant of a security interest or
other direct or indirect disposition or encumbrance of an interest (including by operation of law)
or the rights thereof. The term “Transferred,” and other forms of the word
“Transfer” shall have correlative meanings.

ARTICLE XIX

MISCELLANEOUS

     19.1 Entire Agreement; Amendments. This Agreement, including its recitals and
exhibits, constitutes the entire agreement between the parties hereto and supersedes any and all
prior representations, warranties, statements, promises, agreements and understandings between the
parties hereto, whether oral or written, relating to the subject matter hereof, and no party hereto
shall be bound by nor charged with any written or oral representations, warranties, statements,
promises, agreements and understandings not specifically set forth in this Agreement. No
amendments or modifications of the terms of this Agreement, including any conflicting or additional
terms contained in any sales order, purchase order, acknowledgment form, or other written document
submitted by either party hereto, shall be binding on either party hereto unless reduced to writing
and signed by a duly authorized representative of each party hereto.

     19.2 Notices. All notices given pursuant to this Agreement shall be sent by: (a)
certified mail, return receipt requested, in which case notice will be deemed delivered three (3)
Business Days after deposit, postage prepaid in the United States mail; (b) a nationally recognized
overnight courier, in which case notice will be deemed delivered one (1) Business Day after deposit
with such courier; or (c) personal delivery. Addresses of the parties hereto are as follows:

	 	 	 	 	 

	 

	 	To Rockwell:
	 	Rockwell Medical Technologies, Inc.
	 

	 	 	 	30142 Wixom Road
	 

	 	 	 	Wixom, Michigan 48383
	 

	 	 	 	Attention: Chief Executive Officer
	 
	 	 	 	 
	 

	 	To DaVita:
	 	DaVita Inc.

17

 

	 	 	 	 	 

	 

	 	 	 	15253 Bake Parkway
	 

	 	 	 	Irvine, California 92618
	 

	 	 	 	Attention: Vice-President of Purchasing
	 
	 	 	 	 
	 

	 	With a copy to:
	 	DaVita Inc.
	 

	 	 	 	601 Hawaii Street
	 

	 	 	 	El Segundo, California 90245
	 

	 	 	 	Attention: General Counsel

The above addresses may be changed by written notice to the other party hereto, provided
that no notice of a change of address will be effective until actual receipt of such
notice.

     19.3 Choice of Law. All issues and questions concerning the construction, validity,
enforcement and interpretation of this Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to any choice of law or conflict of
law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would
cause the application of the laws of any jurisdiction other than the laws of the State of Delaware.

     19.4 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY
AND ALL RIGHT TO TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION IN ANY LEGAL PROCEEDING ARISING OUT
OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS OR EVENTS CONTEMPLATED HEREBY OR ANY COURSE OF
CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF ANY PARTY HERETO.
THE PARTIES HERETO EACH AGREE THAT ANY AND ALL SUCH CLAIMS AND CAUSES OF ACTION SHALL BE TRIED BY
THE COURT WITHOUT A JURY. EACH OF THE PARTIES HERETO FURTHER WAIVES ANY RIGHT TO SEEK TO
CONSOLIDATE ANY SUCH LEGAL PROCEEDING IN WHICH A JURY TRIAL HAS BEEN WAIVED WITH ANY OTHER LEGAL
PROCEEDINGS IN WHICH A JURY TRIAL CANNOT OR HAS NOT BEEN WAIVED.

     19.5 Attorneys Fees. In the event of any legal proceeding between the parties hereto
with respect to this Agreement, the enforceability of any of its provisions or any alleged or
actual breach of this Agreement by any party hereto, the prevailing party shall be entitled to
recover reasonable attorney’s fees and all other costs and expenses incurred in connection with
pursuing any action with respect thereto, in addition to any other relief to which such party may
be entitled. The term “prevailing party” shall mean with respect to each claim asserted in a
complaint the party in whose favor final judgment after appeal (if any) is rendered with respect to
such claim asserted in the complaint.

     19.6 Non-Limitation of Rights and Remedies. Except as otherwise expressly provided
herein, the various rights and remedies provided herein shall be cumulative and in addition to any
other rights and remedies the parties hereto may be entitled to pursue at law or equity. The
exercise of one or more of such rights or remedies shall not impair the right of either party
hereto to exercise any other right or remedy at law or equity.

     19.7 Waiver. No waiver by any party hereto, whether express or implied, of its
rights under any provision hereto shall constitute a waiver of the party’s rights under such
provisions at any other time or a waiver of the party’s rights under any other provision hereto.
No failure by any party hereto to take any action against any breach of this Agreement or default
by another party hereto shall constitute a waiver of the former party’s right to enforce any
provision of this Agreement or to take action against

18

 

such breach or default or any subsequent breach or default by the other party hereto. To be
effective any waiver must be in writing and signed by the waiving party.

     19.8 Severability. In the event any provision of this Agreement shall be held to be
invalid or unenforceable in any respect, such provision shall be enforced to the fullest extent
permitted by law and the remaining provisions of this Agreement shall remain in full force and
effect. If any such invalid portion constitutes a material term of this Agreement, the parties
hereto shall meet and in good faith seek to mutually agree to modify this Agreement so as to
retain, if possible, the overall essential terms of this Agreement.

     19.9 Conflicts. To the extent that any provision of any sales order, purchase order,
invoice, or any other document, or the terms of any of Rockwell’s general policies, terms and
conditions, procedures or catalogs, conflict with or alter any term of this Agreement, this
Agreement shall govern and control.

     19.10 Assignment and Transfer. This Agreement will be binding upon and inure to the
benefit of the parties hereto. This Agreement may not be Transferred by any party hereto without
the prior written consent of the other party hereto; provided however that
nothing in this Agreement shall or is intended to limit the ability of DaVita to Transfer this
Agreement, in whole or in part, without the consent of Rockwell to: (a) any Affiliate of DaVita;
(b) any buyer in connection with a Sale of DaVita; or (c) any lenders of DaVita as collateral for
borrowings.

     19.11 Relationship of the Parties. This Agreement is not intended to create and shall
not be construed as creating between Rockwell and DaVita the relationship of Affiliate, principal
and agent, joint venture, partnership, or any other similar relationship, the existence of which is
hereby expressly denied. Neither party hereto shall have (nor shall it hold itself out as having)
any right, power or authority to make or incur any legally binding agreement, obligation,
representation, warranty or commitment on behalf of the other party hereto or to direct any action
of, or activity by the other party hereto or any of its officers, directors, members, managers,
employees or agents.

     19.12 Counterparts; Facsimile/PDF Signatures. This Agreement may be executed in any
number of counterparts and any party hereto may execute any such counterpart, each of which when
executed and delivered shall be deemed to be an original and all of which counterparts taken
together shall constitute but one and the same instrument. This Agreement shall become binding
when one or more counterparts taken together shall have been executed and delivered by each of the
parties hereto. It shall not be necessary in making proof of this Agreement or any counterpart
hereof to produce or account for any of the other counterparts. The parties hereto agree that
facsimile transmission or PDF of original signatures shall constitute and be accepted as original
signatures.

     19.13 Headings and Interpretation. All Section and Article headings contained in this
Agreement are for convenience of reference only, do not form a part of this Agreement and shall not
affect in any way the meaning or interpretation of this Agreement. Words used herein, regardless
of the number and gender specifically used, shall be deemed and construed to include any other
number, singular or plural, and any other gender, masculine, feminine, or neuter as the context
requires. The words “include”, “includes” and “including”, and words of similar import, shall be
deemed to be followed by the phrase “without limitation”. Unless the context expressly by its
terms requires otherwise, (a) any reference to any law herein shall be construed as referring to
such law as from time to time enacted, repealed or amended, (ii) any reference herein to any Person
shall be construed to include such Person’s permitted successors and assigns, (iii) the words
“herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to
this Agreement in its entirety and not to any particular provision

19

 

hereof, and (iv) all references herein to Sections, Articles, or Exhibits shall be construed
to refer to Sections, Articles, or Exhibits of this Agreement.

     19.14 Joint Preparation. Each party hereto: (a) has participated in the preparation
of this Agreement; (b) has read and understands this Agreement; and (c) has been represented by
counsel of its own choice in the negotiation and preparation of this Agreement. Each party hereto
represents that this Agreement is executed voluntarily and should not be construed against any
party hereto solely because it drafted all or a portion hereof.

     19.15 Time of Essence. Rockwell’s obligation to meet the delivery dates or any other
time periods set forth herein is of the essence.

     19.16 Survival. Notwithstanding anything to the contrary that may be contained
elsewhere in this Agreement, this Article XIX and Articles II, VI,
IX, X, XI, XII and XIII shall survive, and remain in full
force and effect, following the expiration or termination of this Agreement for any reason.

     19.17 Business Day. If any payment is due, or any time period for giving notice or
taking action expires, on a day that is not a Business Day, the payment shall be due and payable
on, and the time period for giving such notice or taking such action shall automatically be
extended to, the next succeeding Business Day.

     19.18 Public Announcements . Except as otherwise required pursuant to any applicable
federal or state securities laws or stock listing requirements, no party hereto shall make any
public announcement of any kind or any filing with respect to the other party hereto or any of the
transactions provided for herein without the prior written consent of the other party hereto.
Except as otherwise required pursuant to any applicable federal or state securities laws or stock
listing requirements, any press release or other announcement or notice regarding the other party
hereto or any of the transactions contemplated by this Agreement shall be by joint press release
mutually agreed to in writing by the parties hereto.

[SIGNATURE PAGE FOLLOWS]

20

 

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be effective as of the
Effective Date.

	 	 	 	 	 	 	 

	 
	ROCKWELL:	 	DAVITA:
	 	 	 	 	 	 	 
	 
	ROCKWELL MEDICAL TECHNOLOGIES, INC.	 	DAVITA INC.
	 	 	 	 	 	 	 
	 
	By: 	 /s/ Rob Chioini	 	By: 	 /s/ LeAnn Zumwalt
	 	Print Name: Rob Chioini	 	 	Print Name: LeAnn Zumwalt
	 	Title: 	 CEO	 	 	Title: 	  VP
	 	Time of Signature: 2/16/11 3:40 p.m.	 	 	Time of Signature: 2/16/11
	 	 	 	 	 	 	 
	 	 	 	 	Approved as to form:
	 	 	 	 	 	 	 
	 	 	 	 	DAVITA INC.
	 	 	 	 	 	 	 
	 
	 	 	 	 	By: 	 /s/ Jon Kweller
	 	 	 	 	 	Print Name: Jon Kweller
	 	 	 	 	 	Title:	  Deputy General Counsel

[SIGNATURE
PAGE TO PRODUCTS PURCHASE AGREEMENT]

 

EXHIBIT A

PRODUCTS AND PURCHASE PRICE

See attached.

A-1

 

EXHIBIT A; 2011

Price Quote Standard Formulas

	 	 	 	 	 	 	 	 	 
	CATALOG #	 	DESCRIPTION	 	PACKAGING	 	UNIT	 	PRICE
	 
	[*               *]
	 	 	 	 	 	 	 	 
	[*               *]

	 	 	 	25 Gallon Case
	 	Case
	 	[*     *]
	 
	 	 	 	 	 	 	 	 
	[*               *]
	 	 	 	 	 	 	 	 
	[*               *]

	 	 	 	55 Gallon Drum
	 	Drum
	 	[*     *]
	[*               *]

	 	 	 	4 Gal/cs 3.785lt/gal
	 	Case
	 	[*     *]
	 
	 	 	 	 	 	 	 	 
	[*               *]
	 	 	 	 	 	 	 	 
	[*               *]

	 	 	 	2.1 Gallon Bag 20/cs
	 	Case
	 	[*     *]
	[*               *]

	 	 	 	15 Gallon Bag 4/cs
	 	Case
	 	[*     *]
	[*               *]

	 	 	 	25 Gallon Bag 2/cs
	 	Case
	 	[*     *]
	 
	 	 	 	 	 	 	 	 
	[*               *]
	 	 	 	 	 	 	 	 
	[*               *]

	 	 	 	4 Gallon Case
	 	Case
	 	[*     *]
	 
	 	 	 	 	 	 	 	 
	[*               *]
	 	 	 	 	 	 	 	 
	[*               *]

	 	 	 	25 Gallon Case
	 	Case
	 	[*     *]
	 
	 	 	 	 	 	 	 	 
	[*               *]
	 	 	 	 	 	 	 	 
	[*               *]

	 	 	 	55 Gallon Drum
	 	Drum
	 	[*     *]
	[*               *]

	 	 	 	4 Gal/cs 3.785lt/gal
	 	Case
	 	[*     *]
	 
	 	 	 	 	 	 	 	 
	[*               *]
	 	 	 	 	 	 	 	 
	[*               *]

	 	 	 	4 Gallon Case
	 	Case
	 	[*     *]
	[*               *]

	 	 	 	50lb Bag
	 	Bag
	 	[*     *]
	[*               *]

	 	 	 	25lb Bag
	 	Bag
	 	[*     *]
	 

NOTE:

	•	 	Dry Acid Mixers for Dri-Sate® and CitraPure Dry Acid:

	 	 	 	 	 	 	 

	 

	 	DSMIX-50
	 	Dry Acid Mixer, 50 Gal
	 	[*     *]
	 

	 	DSMIX-100
	 	Dry Acid Mixer, 100 Gal
	 	[*     *]

	•	 	Drum prices include [*     *].

30142 Wixom Road o Wixom, MI 48393 o (248) 960-9009 o Fax (248) 960-9119 o (800) 449-3353

A-2

 

EXHIBIT B

TERRITORY

See attached.

B-1

 

EXHIBIT B; 2011

The purchase price for the Products as set forth on Exhibit A is applicable in the
following [*     *]:

[*     *]

[*     *]

30142 Wixom Road o Wixom, MI 48393 o (248) 960-9009 o Fax (248) 960-9119 o (800) 449-3353

B-2

 

EXHIBIT C

DAVITA SHIPPING AND ORDER REQUIREMENTS

See attached.

C-1

 

EXHIBIT C; 2011

DAVITA SHIPPING & ORDERING GUIDELINES

GENERAL GUIDELINES APPLICABLE TO ALL PRODUCTS (DRI-SATE® DRY ACID CONCENTRATE,
RENALPURE® LIQUID ACID CONCENTRATE, RENALPURE® BICARBONATE POWDER,
STERILYTE® LIQUID BICARBONATE, CITRAPURE®  DRY ACID and LIQUID ACID
CONCENTRATE and CLEANING AGENTS)

	1.	 	Lead time from the initial order from a DAVITA dialysis clinic to the first delivery is [*               *].
	 
	2.	 	If DAVITA fails to maintain adequate inventory of a particular Product, or fails to place an order for a particular Product [*               *], resulting in ROCKWELL shipping the Products via a third party carrier, [*               *].
	 
	3.	 	[*               *] shall pay all return freight costs due to Products shipped in error and/or Products damaged prior to receipt by DAVITA; otherwise, [*               *] shall pay [*               *].
	 
	4.	 	Orders for Products must be received via facsimile at [*               *], otherwise a charge of [*               *] will be applied [*          
     *]. Each of DAVITA’s dialysis clinics shall [*       
        *].

	 
	5.	 	ROCKWELL shall [*               *].
	 
	6.	 	ROCKWELL shall [*               *].

NOTE: The minimum order requirement in the aggregate for all Products combined (liquid and dry acid
concentrate, bicarbonate powder, SteriLyte and cleaning agents) is [*     *].

SPECIFIC ADDITIONAL GUIDELINES FOR CERTAIN PRODUCTS

DRY ACID CONCENTRATE

	1.	 	Special formulas of Dri-Sate® Dry Acid Concentrate, if approved, [*               *].

LIQUID ACID CONCENTRATE

	1.	 	Special formulas of Liquid Acid Concentrate, if approved, [*               *].
	 
	2.	 	With respect to Liquid Acid Concentrate, DAVITA will be responsible for a [*               *].

30142 Wixom Road o Wixom, MI 48393 o (248) 960-9009 o Fax (248) 960-9119 o (800) 449-3353

C-2

 

EXHIBIT D

RETURN GOODS POLICY

See Item 3 of Exhibit C.

D-1

 

EXHIBIT E

WARRANT

See attached.

E-1

 

THIS STOCK PURCHASE WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR ANY STATE SECURITIES LAWS. IT MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE
OF REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES
LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
THIS WARRANT IS ALSO SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 HEREOF.

WARRANT TO PURCHASE SHARES

OF COMMON STOCK, NO PAR VALUE, OF

ROCKWELL MEDICAL TECHNOLOGIES, INC.

February 16, 2011

     THIS STOCK PURCHASE WARRANT (“Warrant”) CERTIFIES THAT, for value received, subject to the
provisions hereinafter set forth, DaVita Inc. (the “Holder”) is entitled to purchase from Rockwell
Medical Technologies, Inc., a Michigan corporation, and its successors and assigns (the “Company”)
up to 100,000 shares (the “Warrant Shares”) of common stock of the Company, no par value (the
“Common Stock”). This Warrant is the “Warrant Agreement” issued in accordance with that certain
Products Purchase Agreement, dated as of February 16, 2011, between the Company and Holder (the
“Agreement”). This Warrant is subject to the provisions and adjustments, and exercise hereof is
subject to and will be made on the terms and conditions, hereinafter set forth.

     The following is a statement of the rights of the Holder of this Warrant and the terms and
conditions to which this Warrant is subject, to which terms the Holder hereof, by acceptance of
this Warrant, assents.

1. EXERCISE OF WARRANT

     (a) The Warrant shall become exercisable in full on the first day immediately following the
end of the Initial Term (as defined in the Agreement) (the “Exercise Date”). The exercise price
for the Warrant Shares is $10.25 per share (the “Exercise Price”). On and after the Exercise Date,
subject to the conditions set forth herein, this Warrant may be exercised in whole at any time or
in part from time to time until the close of business on the Expiration Date (as defined below) by
the Holder by the surrender of this Warrant at the principal office of the Company, accompanied by
a signed notice of exercise in the form attached hereto and payment to the Company of the Exercise
Price in the manner set forth below for each of the Warrant Shares intended to be purchased. Such
payment shall be made by Holder to the Company in the form of cash, a certified or cashier’s check
or by means of the cashless method described in Section 1(b) of this Warrant. Notwithstanding any
other provision in this Warrant to the contrary, this Warrant shall not be deemed exercised until
payment in full of the applicable Exercise Price for the

E-2

 

Warrant Shares to be purchased has been
received by the Company as specified in this Section 1. The Warrant will expire at the earlier of
(i) the close of business on the 90th day immediately following the completion of the
Initial Term (as defined in the Agreement), or (ii) the termination of the Agreement by the Company
pursuant to Section 2.4 thereof (the earlier of such dates being the “Expiration Date”). If the
Expiration Date shall occur prior to the Exercise Date, the Warrant shall expire without becoming
exercisable.

     (b) The Holder may exercise the Warrant by the surrender of this Warrant at the principal
office of the Company on or before the Expiration Date together with a written notice of cashless
exercise, in which event the Company shall issue to the Holder the number of shares of Common Stock
determined as follows:

	X = 	(Y x (A-B))/A

	where:

	X = 	the number of shares of Common Stock to be issued to the Holder;

	Y = 	the number of Warrant Shares with respect to which this Warrant is being exercised;

	A = 	the average of the high and low trading prices per share of the Common Stock on the Nasdaq
Stock Market for the five trading days immediately preceding (but not including) the date of
exercise.

	B =  	the Exercise Price (as adjusted to the date of such calculation).

2. ADJUSTMENTS

     (a) In the event the Company shall (i) pay a dividend to the holders of Common Stock in shares
of Common Stock, (ii) subdivide its outstanding shares of Common Stock into a greater number of
shares, or (iii) combine its outstanding shares of Common Stock into a smaller number of shares,
then (A) the number of Warrant Shares that, at such time, remain available for purchase pursuant to
this Warrant (“Available Warrant Shares”) shall be adjusted so that such amount is equal to the
number of shares of Common Stock which Holder would have owned immediately after such event had the
number of Available Warrant Shares immediately prior to the occurrence of such event been owned on
the record date for such event and (B) the Exercise Price shall be adjusted by multiplying the
Exercise Price in effect immediately prior to such event by a fraction (x) the numerator of which
is the total number of outstanding shares of Common Stock immediately prior to such event, and (y)
the denominator of which shall be the total number of outstanding shares of Common Stock
immediately after such event. Such adjustment shall become effective immediately after the opening
of business on the day following such record date or the day upon which such dividend, subdivision
or combination becomes effective.

     (b) In the event the Company shall (i) issue by reclassification of its Common Stock any
shares of the Company of any class or series, (ii) merge or consolidate with or into another entity
(other than a merger in which the Company is the surviving entity and which does not result in any
reclassification of the outstanding shares of Common Stock), (iii) sell or otherwise convey to
another entity all or substantially all of the assets of the

3

 

Company followed by the distribution
of the proceeds thereof to the shareholders of the Company, or (iv) engage in a share exchange
involving all or substantially all of the stock of the Company, then the Holder shall thereafter be
entitled to receive upon the exercise of this Warrant, instead of the Available Warrant Shares, the
consideration which the Holder would have owned immediately after such event had the Available
Warrant Shares been owned immediately prior to the occurrence of such event.

     (c) No adjustment shall be required unless such adjustment would require an increase or
decrease of at least one-tenth of a share in the number of Warrant Shares, or at least one-tenth of
a cent in the Exercise Price; provided, however, that any adjustment which by reason hereof is not
required to be made shall be carried forward and taken into account in any subsequent adjustment.

     (d) No fractional shares of Common Stock shall be issued upon exercise of this Warrant. The
number of shares issued shall instead be rounded down to the nearest whole share and any fractional
share disregarded.

     (e) In the event that, as a result of an adjustment made pursuant to this Section 2, the
Holder shall become entitled to receive any shares of capital stock of the Company other than
shares of Common Stock, the number of such other shares so receivable upon exercise of this Warrant
shall be subject thereafter to adjustment from time to time in a manner and on terms as nearly
equivalent as practicable to the provisions with respect to the Warrant Shares contained in this
Warrant.

     (f) The Company shall not, by amendment of its Articles of Incorporation or through any
reorganization, recapitalization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms to be observed or performed hereunder by the Company, but will at
all times in good faith assist in the carrying out of all of the provisions of this Section 2.

3. FULLY PAID STOCK

     The Company agrees that the Warrant Shares delivered upon exercise of this Warrant as herein
provided shall, at the time of such delivery, be fully paid and non-assessable, and free from all
liens and charges with respect to the purchase thereof. During the period within which this
Warrant may be exercised for Common Stock, the Company will at all times have authorized, and hold
in reserve for issuance upon exercise of this Warrant, a sufficient number of shares of Common
Stock to provide for the exercise of this Warrant.

4. LOST OR STOLEN WARRANTS

     In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall issue a
new Warrant of like date, tenor, and denomination and deliver the same in exchange and substitution
for and upon surrender and cancellation of any mutilated

4

 

Warrant, or in lieu of the lost, stolen or
destroyed Warrant, upon receipt of an indemnity agreement or bond from Holder reasonably
satisfactory to the Company.

5. ASSIGNMENT

     This Warrant may not be Transferred (as defined below) without the prior written consent of
the Company; provided, however, that if the Agreement is Transferred in accordance with the terms
thereof, this Warrant may be Transferred to the transferee of the Agreement. A “Transfer” means any
sale, transfer, assignment, pledge, mortgage, exchange, hypothecation, grant of a security interest
or other direct or indirect disposition or encumbrance of an interest (including by operation of
law) or the rights thereof. The Company shall deem and treat the Holder (or any successor holder
to whom this Warrant is Transferred in accordance with this Section 5) as the absolute owner of
this Warrant, notwithstanding any notations of ownership or writing hereon made by anyone other
than the Company, for all purposes and shall not be affected by any notice to the contrary. Any
attempted Transfer of this Warrant without compliance with this Section 5 shall be null and void.

6. SECURITIES MATTERS

     (a) Neither this Warrant nor the Warrant Shares have been registered under the Securities Act
of 1933, as amended (the “Act”), or any applicable “Blue Sky” laws.

     (b) By exercising this Warrant, Holder (or any successor holder to whom this Warrant is
Transferred in accordance with Section 5) is deemed to represent and warrant to the Company that
(i) Holder is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the
Act and was not organized for the purpose of acquiring the Warrant or the Warrant Shares; (ii)
Holder’s financial condition is such that it is able to bear the risk of holding the Warrant Shares
for an indefinite period of time and could afford a complete loss on such investment; (iii) Holder
has sufficient knowledge and experience in investing in companies similar to the Company so as to
be able to evaluate the risks and merits of its investment in the Company and has so evaluated the
risks and merits of such investment, understands that an investment in the Warrant Shares involves
a significant degree of risk, including a risk of total loss of Holder’s investment, and
understands the risk factors included, or that may be included in the future, in the Company’s
periodic reports filed from time to time with the Securities and Exchange Commission; (iv) Holder
acknowledges that the Company has made available copies of its annual, quarterly and other reports
and documents filed with the Securities and Exchange Commission pursuant to Sections 13(a), 14(a),
14(c) and 15(d) of the Securities Exchange Act of 1934, as amended, and the information
incorporated in such reports and documents by reference, and acknowledges that, a reasonable time
before Holder’s exercise of the Warrant, it has reviewed such reports and documents, has had the
opportunity to ask questions about the Company and the Warrant Shares, that such questions have
been answered to Holder’s satisfaction, and that it has obtained all other information with respect
to an investment in the Warrant Shares that it has requested from the Company; and (v) Holder is
acquiring the Warrant Shares for its own account for investment and not for resale or with a view
to distribution thereof in

5

 

violation of the Securities Act of 1933. Except to the extent that the
sale of the Warrant Shares by the Company upon exercise of the Warrant has been registered under
the Act, each and every certificate representing Warrant Shares delivered upon exercise of this
Warrant shall bear the following legend:

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE
OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF
COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

     (c) Anything to the contrary herein notwithstanding, the Company’s obligation to sell and
deliver Common Stock pursuant to the exercise of this Warrant is subject to its receipt of
satisfactory assurance that the issuance of such shares shall not violate any of the provisions of
the Act or the rules and regulations of the Securities and Exchange Commission promulgated
thereunder. No Warrant Shares shall be issued until counsel for the Company has determined that
the Company has complied with all requirements under applicable securities laws.

7. NO RIGHTS AS SHAREHOLDER

     Nothing contained in this Warrant shall be construed as conferring upon the Holder any rights
as a shareholder of the Company.

8. MISCELLANEOUS

     (a) All covenants and agreements of the Company in this Warrant shall be binding upon the
Company’s successors and assigns. All covenants and provisions hereof by or for the benefit of the
Holder shall bind and inure to the benefit of its successors and permitted assigns hereunder.

     (b) This Warrant shall be construed and enforced in accordance with the laws of the State of
Michigan without regard to choice of law principles that would compel the application of the law of
any other jurisdiction.

     (c) Except as provided in Section 2, this Warrant may be amended only with the written consent
of the Company and the Holder.

     (d) Any notices or other communications required or permitted hereunder shall be sufficiently
given if in writing and delivered in person or sent by United States mail, by registered mail,
postage prepaid, or by courier or express delivery service (including, without limitation, Federal
Express and UPS), and if to the Holder, addressed to the Holder at 15253 Bake Parkway, Irvine,
California 92618, Attention: Vice-

6

 

President of Purchasing, and if to the Company, addressed to it
at 30142 Wixom Road, Wixom, Michigan 48393, Attention: Chief Financial Officer, or to such other
address or attention as shall be furnished in writing by the Company or the Holder. Any such notice
or other communication shall be deemed to have been given as of the date received.

     (e) In the event of any conflict between this Warrant and the Agreement, the terms of this
Warrant shall control.

7

 

     IN WITNESS WHEREOF, the undersigned has caused this Warrant to be signed by a duly authorized
officer and this Warrant to be dated as of the date set forth above.

ROCKWELL MEDICAL TECHNOLOGIES, INC.

By: __________________________

Its: __________________________

8

 

NOTICE OF EXERCISE

Rockwell Medical Technologies, Inc.

30142 Wixom Road

Wixom, Michigan 48393

Attention: Chief Financial Officer

     A Warrant was issued to the undersigned as of February 16, 2011 to purchase up to 100,000
shares of Rockwell Medical Technologies, Inc. common stock at the exercise price set forth in the
Warrant. The undersigned hereby elects to exercise the Warrant with respect to ____________
shares. Payment of the exercise price is being made by (check one):

	 	 	o cash;

	 	 	o certified or cashier’s check delivered with this notice;

	 	 	o cashless exercise method described in Section 1(b) of the Warrant.
The stock certificate for the shares acquired upon exercise should be issued to:

	 	 	 	 
	 	 	 	 
	(name)   
	 	 	 
	 

	 	 	 
	(address)
	 	 	 
	 

	 	 	 
	 
	 	 	 
	 

	 	 	 
	(Social Security No. or EIN)
	 	 	 
	 

	 	 	 

	 	 	 	 	 	 
	 	 	 	 
	 

	 	By:	 	 	 
	 

	 	 	 	 	 
	 

	 	Its:	 	 	 
	 

	 	 	 	 	 
	 

	 	Dated:	 	 	 
	 

	 	 	 	 	 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]